Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects

Emalex Biosciences

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteer

Treatments: Drug: [14C]-Ecopipam

Study type: Interventional

Funder types: Industry

Identifiers

NCT04881955

EBS-101-HV-103

Details and patient eligibility

About

Phase 1, single-center (United Kingdom), open-label, nonrandomized, single-dose study in healthy adult male subjects to assess the absorption, metabolism, and excretion of [14C]-Ecopipam in Healthy Male Subjects.

Full description

This study will be a Phase 1, open-label, nonrandomized, single-dose study in healthy male subjects. Potential subjects will be screened to assess their eligibility to enter the study within 29 days prior to dose administration. Subjects will be admitted into the clinical research unit (CRU) on Day -1 and be confined to the CRU until at least Day 8 (Discharge). On Day 1, subjects will receive a single oral dose of 200 mg ecopipam HCl containing approximately 88.5 µCi of [14C]-ecopipam HCl. Subjects will be discharged when the following discharge criteria are met:

• plasma radioactivity levels below the limit of quantitation for 2 consecutive collections;
• ≥ 90% mass balance recovery; and
• ≤ 1% of the total radioactive dose is recovered in combined excreta (urine and feces) in 2 consecutive 24-hour periods in which collections occur. If discharge criteria are not met on Day 8, subjects will remain in the CRU and additional 24-hour collections (blood, urine, and feces) for total radioactivity will continue until these criteria are met, up to a maximum of Day 15.

Enrollment: 8 patients

Sex: Male

Ages: 35 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males of any race between 35 and 55 years of age
• Body mass index between 18.0 and 30.0 kg/m2
• In good health
• Males will agree to use contraception
• Able to comprehend and sign an informed consent form
• History of a minimum of 1 bowel movement per day

Exclusion criteria

• History of significant medical illness
• History of clinically significant drug allergy
• History of a seizure disorder, not including infantile seizures
• History of stomach or intestinal surgery that would potentially alter absorption and/or excretion of orally administered drugs
• Clinically significant medical treatment within 8 weeks or infection treatment within 4 weeks of dosing
• Clinically significant ECG abnormality
• History of alcoholism or drug/chemical abuse within the previous 2 years or positive screening test
• Significant alcohol consumption
• Positive hepatitis panel and/or positive human immunodeficiency virus test
• Use of prohibited prescription, over-the-counter medications or natural health products
• Use of tobacco or nicotine-containing products within 3 months prior to Check-in or positive screening test
• Receipt of blood products within 2 months prior to Check in
• Recent donation of blood, plasma, or platelets prior to Screening
• Exposure to significant diagnostic, therapeutic or employment in a job requiring radiation exposure monitoring within 12 months prior to Check-in
• Evidence or history of active suicidal thoughts in the previous 5 years or have any lifetime history of a suicide attempt
• Not suitable for study in the opinion of the Principal Investigator

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

[14C]-Ecopipam

Experimental group

Description:

Single oral capsule dose of 200 mg ecopipam HCl containing approximately 88.5 µCi of \[14C\]-ecopipam HCl

Treatment:

Drug: [14C]-Ecopipam